Berkay Alpay

Berkay Alpay

Auto-generated profile, based on publicly available information

Berkay Alpay

Department of Neurology, Danish Headache Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Cephalalgia
Verified
Journal Article
Open access
BABerkay Alpay
Berkay Alpay
RCRune Häckert Christensen
Rune Häckert Christensen
HAHaidar M. Al-Khazali
Haidar M. Al-Khazali
MAMessoud Ashina
Messoud Ashina
HAHåkan Ashina
Håkan Ashina
Substance P, a neuropeptide associated with pain and inflammation, has been implicated in migraine pathophysiology through its action within the trigeminovascular system. This narrative review summarizes current evidence on the synthesis, release, receptor binding and downstream effects of substance P. It integrates preclinical and clinical findings to reassess its therapeutic relevance. Substance P is released from primary afferent neurons and acts on neurokinin-1 receptors, which are widely expressed in both peripheral tissues and central pain-processing regions. In the meninges, substance P contributes to vasodilation, plasma protein extravasation, mast cell degranulation and immune cell recruitment, all of which facilitate neurogenic inflammation and possibly lower the activation threshold of meningeal nociceptors. In the central nervous system, substance P promotes excitatory neurotransmission, potentiates glutaminergic activity and attenuates inhibitory GABAergic signaling, cumulatively amplifying pain transmission. Preclinical studies consistently demonstrate that neurokinin-1 receptors antagonists inhibit substance P-induced responses, such as neurogenic inflammation and neuronal activation, supporting their therapeutic potential. However, randomized controlled trials with neurokinin-1 receptors antagonists were not superior to placebo in treating migraine. A re-appraisal of these trials reveal that the disappointing results might be due to methodologic shortcomings, including underpowered samples and suboptimal efficacy endpoints. A recent randomized, double-blind, placebo-controlled, two-way crossover study showed that intravenous infusion of substance P is potent inducer of headache and arterial dilation in healthy adults. These findings align with the established biological functions of substance P and warrant renewed therapeutic interest. Advances in translational research, particularly those emphasizing direct measurement of meningeal nociceptor activity and refined clinical trial design, might overcome past limitations and clarify the role of substance P in migraine. The dismissal of substance P signaling as a therapeutic target might thus have been premature. Renewed efforts might uncover novel therapeutic strategies, offering hope for patients with migraine who remain unresponsive to existing treatment.

18 February 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
EAEzgi̇ Deni̇z Arikan
Ezgi̇ Deni̇z Arikan
BÇBarişcan Çi̇mEn
Barişcan Çi̇mEn
AYAyşe Ece Gezen Yilmaz
Ayşe Ece Gezen Yilmaz
EAEli̇f Akaydin
Eli̇f Akaydin
BABerkay Alpay
Berkay Alpay
YSYildirim Sara
Yildirim Sara
Background/aimPeripheral nerve injuries (PNI) are debilitating disorders affecting predominantly the younger generation, often leading to significant disabilities. Current treatment strategies are inadequate in addressing the complex nature of these injuries. Peripheral nerve healing and functional recovery are crucial components of both pathophysiology and therapeutic approach. High fructose corn syrup (HFCS) is a frequently used sweetener in several beverages and foods. And it is associated with several metabolic disturbances including insulin resistance and may impair nerve healing. This study investigates the therapeutic role of ivermectin on nerve regeneration following sciatic nerve injury and evaluates motor and sensorial functions together with histopathological evaluation. Additionally, we aimed to compare nerve healing between animals that consume high-fructose and those that do not.Materials and methodsForty-eight male Swiss albino mice were randomly divided into six groups, first-half consuming HFCS-42 (11% v/v) and the second-half regular tap-water for 8 weeks. On 28th day, sciatic nerve injury (SNI) was performed on all groups. Ivermectin (1 mg/kg) or gabapentin (30 mg/kg) treatments were administered to selected groups. Body weight, blood glucose, motor function (Rotarod, open field test) and thermal-mechanical sensorial functions were assessed weekly. Finally, insulin levels were measured, and histopathological samples were taken.Results8 weeks of HFCS impaired mechanical-thermal sensorial functions with histopathologically poor nerve repair. Ivermectin resulted in improved sensorial and faster motor function recovery in HFCS groups. Elevated plasma insulin levels-HOMA-IR values were diminished by ivermectin in HFCS groups. In ivermectin non-HFCS group, histopathology revealed accelerated healing and higher scores in total. Ivermectin also ameliorated mechanical sensation loss after SNI alongside with cold sensation.ConclusionIvermectin accelerated sensorial and motor nerve recovery resulting in faster nerve healing alongside improved insulin-resistance, suggesting it might serve as a potential foundation for developing a new treatment for nerve regeneration after injury.

14 April 2023
Verified
Book Chapter
Closed access
PDF file
BABerkay Alpay
Berkay Alpay
BCBariscan Cimen
Bariscan Cimen
YSYildirim Sara
Yildirim Sara